A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

The astonishing clinical success of CD19 chimeric antigen receptor (CAR) T-cell therapy has led to the approval of two second generation chimeric antigen receptors (CARs) for acute lymphoblastic leukemia (ALL) andnon-Hodgkin lymphoma (NHL). The focus of the field is now on emulating these successes...

Descripción completa

Detalles Bibliográficos
Autores principales: Kueberuwa, Gray, Zheng, Weiming, Kalaitsidou, Milena, Gilham, David E., Hawkins, Robert E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MyJove Corporation 2018
Materias:
Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6235544/
https://www.ncbi.nlm.nih.gov/pubmed/30394400
http://dx.doi.org/10.3791/58492

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6235544/
https://www.ncbi.nlm.nih.gov/pubmed/30394400
http://dx.doi.org/10.3791/58492

Ejemplares similares